BRCA1 and BRCA2 missense variants of high and low clinical significance influence lymphoblastoid cell line post-irradiation gene expression.
The functional consequences of missense variants in disease genes are difficult to predict. We assessed if gene expression profiles could distinguish between BRCA1 or BRCA2 pathogenic truncating and missense mutation carriers and familial breast cancer cases whose disease was not attributable to BRC...
Main Authors: | Nic Waddell, Anette Ten Haaf, Anna Marsh, Julie Johnson, Logan C Walker, kConfab Investigators, Milena Gongora, Melissa Brown, Piyush Grover, Mark Girolami, Sean Grimmond, Georgia Chenevix-Trench, Amanda B Spurdle |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2008-05-01
|
Series: | PLoS Genetics |
Online Access: | http://europepmc.org/articles/PMC2375115?pdf=render |
Similar Items
-
Use of DNA-damaging agents and RNA pooling to assess expression profiles associated with BRCA1 and BRCA2 mutation status in familial breast cancer patients.
by: Logan C Walker, et al.
Published: (2010-02-01) -
Searching for BRCA3 by exome sequencing
by: Makunin I, et al.
Published: (2012-04-01) -
Missense variants of uncertain significance (VUS) altering the phosphorylation patterns of BRCA1 and BRCA2.
by: Eric Tram, et al.
Published: (2013-01-01) -
In silico analysis of BRCA1 and BRCA2 missense variants and the relevance in molecular genetic testing
by: Kok-Siong Poon
Published: (2021-05-01) -
Multifactorial likelihood assessment of BRCA1 and BRCA2 missense variants confirms that BRCA1:c.122A>G(p.His41Arg) is a pathogenic mutation.
by: Phillip J Whiley, et al.
Published: (2014-01-01)